ANDA consolidation policy
Executive Summary
FDA reminds generic firms that after Jan. 1, 1991, they will be required to submit multiple strengths and variations of a drug in a single application. The policy guide, issued in May, which outlines the requirements, states that exceptions to the rule must be precleared by the agency.